Introduction
============

Hypertrophic pulmonary osteoarthropathy (HPOA) is a condition that is characterized by finger clubbing, joint pain and swelling, and periosteal proliferation of the long bones and largely affects patients with underlying pulmonary diseases. The most common cause of secondary HPOA is pulmonary malignancy.[@b1-ott-10-5173] The incidence of HPOA among lung cancer patients ranged from 0.72% to 17%.[@b2-ott-10-5173],[@b3-ott-10-5173] However, currently, the exact mechanism and molecular pathogenesis of HPOA remain unclear. The literature presents two hypotheses: a neurogenic pathway and a biochemical pathway. A previous study reported that a unilateral vagotomy conducted to interrupt the afferent neural pathway over the affected side of the malignancy effectively relieved joint pain in patients with HPOA.[@b4-ott-10-5173] Therefore, a neural pathway was considered to be involved in the pathogenesis of HPOA. However, some researchers reported that abnormal production of hypoxia-induced agents, including platelet-derived growth factor (PDGF), prostaglandin E2 (PGE2), and vascular endothelial growth factor (VEGF) in patients with HPOA, was observed.[@b5-ott-10-5173] Therefore, subsequently, patients with primary familial hypertrophic osteoarthropathy and neonates with congenital heart disease were prescribed long-term PGE2 injections owing to the possibility of a biochemical pathway.[@b6-ott-10-5173],[@b7-ott-10-5173]

The discovery of the epidermal growth factor receptor (EGFR) mutation as a major driver oncogene in certain lung adenocarcinomas is one of the most important advancements in lung cancer treatment over the past 20 years. Because HPOA is associated with higher serum levels of PDGF, PGE2, and VEGF, and because these factors could activate the EGFR pathway, one can assume that the tumor cells in lung cancer patients with HPOA may be less dependent on the EGFR pathway. However, information regarding EGFR status in lung cancer patients with HPOA is scarce. Therefore, the present study examined the incidence, clinical characteristics, and EGFR mutation status of lung cancer patients with HPOA in Taiwan.

Methods
=======

Patients
--------

This study included patients with pathologically confirmed primary lung cancer who underwent bone scintigraphy between January 2010 and December 2016 for staging. The pathological analyses were conducted at Chiayi and Kaohsiung Chang Gang Memorial Hospital, two large teaching hospitals in Taiwan. For the standard bone scintigraphy, patients received a parenteral injection with 740 MBq (20 mCi) Tc-99m-hydroxymethylene diphosphate; static images were obtained after 3--6 hours. Medical records were reviewed to exclude major causes of HPOA other than lung cancer. For the purpose of the study, HPOA was defined as typical diffuse, symmetrical, and increased linear uptake in the cortical margins of the long tubular bones on bone scintigraphy.

We retrospectively reviewed clinical data including histological type, age at diagnosis, gender, smoking history, EGFR mutation subtype, and clinical stage. Clinical stage was evaluated independently by experienced radiologists according to the *Cancer Staging Manual of the American Joint Committee on Cancer* 7th edition and confirmed by a multidisciplinary team committee. The institutional review board of Chang Gung Memorial Hospital approved this study and deemed written informed consent not necessary due to the retrospective nature of this study (201700522B0). Nonetheless, patient anonymity and confidentiality were maintained throughout the study.

EGFR mutation analysis
----------------------

We extracted tumor DNA from formalin-fixed, paraffin-embedded tissue with the Qiagen QIAamp DNA Mini Kit (QIAGEN^®^, Crawley, UK). EGFR mutations were analyzed via direct sequencing and/or the Scorpion Amplification Refractory Mutation System-based EGFR mutation detection kit (Therascreen EGFR RGQ PCR kit; QIAGEN), which detects 29 mutations across the EGFR gene. The analyses were performed at 3 central laboratories at the Linkou, Kaohsiung, and Chiayi Chang Gang Memorial Hospital.

Results
=======

Between January 2010 and December 2016, a total of 42,314 patients underwent bone scintigraphy. Among them, 93 demonstrated typical HPOA findings on bone scintigraphy, and 24 were excluded because of underlying diseases other than lung cancer (eg, hepatocellular carcinoma, nasopharyngeal carcinoma, soft tissue sarcoma, esophageal cancer, thymic carcinoma, cervical cancer, breast cancer, cholangiocarcinoma, melanoma, hypercalcemia, and liver cirrhosis). Moreover, 69 (74.19%) patients were diagnosed with lung cancer-related HPOA. Concurrently, 5,386 patients were diagnosed with lung cancer at the Chiayi and Kaohsiung Chang Gang Memorial Hospital, yielding an incidence rate of lung cancer patients with HPOA of around 1.28%.

The clinical characteristics of the 69 lung cancer patients with HPOA are listed in [Table 1](#t1-ott-10-5173){ref-type="table"}. Among them, 56 were male (81.2%) and 51 were ex-smokers or current smokers (73.9%). The median age of the male patients was 61 years, which was older than that of the female patients (53 years). Adenocarcinoma was the most common histology subtype (n=42, 60.9%), followed by squamous cell carcinoma (n=12; 17.4%). In addition, 55 (79.7%) patients had stage IIIb or IV disease and only 7 (10.1%) had stage I or II disease. Of the 34 patients with adenocarcinoma (34/42, 81.0%) who were subjected to EGFR mutation analyses, only 4 (11.8%) had EGFR-tyrosine kinase inhibitor (EGFR-TKI)-sensitive mutations, 2 (5.9%) had exon 21 point mutations (L858R), and 2 (5.9%) had exon 19 deletions. Among patients with EGFR-TKI-sensitive mutations, 1 refused further treatment and was lost to follow-up. One woman with stage Ib disease underwent surgical resection but did not receive adjuvant chemotherapy. Recurrent lung cancer with bone metastasis was detected 14.6 months later in January 2012 in 2 patients with stage IIIb and IV lung cancer who received first-line EGFR-TKIs. The treatment outcomes are summarized in [Table 2](#t2-ott-10-5173){ref-type="table"}.

Discussion
==========

Most of the HPOA patients in our study were male and/or ex-smokers or current smokers, which is consistent with the results of previous studies. Moreover, the incidence of EGFR-TKI-sensitive mutations in this population was extremely low. To our knowledge, this is the first study to identify an association between HPOA and EGFR mutation status.

We systemically reviewed previously reported case series and selected those involving more than 10 patients for comparison ([Table 3](#t3-ott-10-5173){ref-type="table"}). The incidence of HPOA in lung cancer patients ranged from 0.8% to 4.5% according to published reports, although Morgan et al[@b3-ott-10-5173] reported an incidence rate of 17% in 1996. In the present study, the incidence of HPOA among lung cancer patients was around 1.2%, which is similar to that demonstrated by Qian and Qin.[@b18-ott-10-5173] This can be explained by the similarity in the race-ethnicity of the cohort and geographic location between the studies.

According to previous reports in Taiwan,[@b8-ott-10-5173]--[@b10-ott-10-5173] only 54.7%--65.5% of patients with lung cancer are male and 43%--45% patients are smokers. The molecular mechanism of HPOA is not yet completely well established. Some hypoxia-associated cytokines or growth factors, including PDGF, PGE2, and VEGF, were thought to be involved in the development of periostosis and digital clubbing in different diseases including right to left shunt,[@b11-ott-10-5173] abdominal aortic aneurysm,[@b15-ott-10-5173] and ulcerative colitis.[@b16-ott-10-5173] Protein products of the 15-hydroxyprostaglandin dehydrogenase (*HPGD*) gene and solute carrier organic anion transporter family member 2A1 gene (SLCO2A1) convert PGE2 into its metabolite 13,14-dihydro-15-ketoprostaglandin E2. Mutation of the HPGD[@b12-ott-10-5173] and SLCO2A1[@b13-ott-10-5173] genes has been reported to be associated with familial primary hypertrophic osteoarthritis. Since smoking causes elevation of serum levels of PGE2 and increase major metabolites concentration in urine sample,[@b14-ott-10-5173],[@b17-ott-10-5173] it may be associated with periostosis and digital clubbing among male lung cancer patients.[@b14-ott-10-5173]

Adenocarcinoma was the most common histological subtype in all the lung cancer patients irrespective of gender: 60.5% and 81.4% for male and female lung cancer patients, respectively.[@b8-ott-10-5173] Adenocarcinoma was also the most common histological type in all lung cancer patients with HPOA. In this study, 42 (60.9%) HPOA patients had adenocarcinoma, and 12 (17.4%) had squamous cell carcinoma. However, among the lung cancer patients with HPOA, the incidence of adenocarcinoma was comparable in males (62.5% vs 60.5%), but much lower in females (53.8% vs 81.4%). Compared with previously published HPOA studies,[@b2-ott-10-5173],[@b3-ott-10-5173],[@b18-ott-10-5173]--[@b20-ott-10-5173] the percentage of adenocarcinoma was much higher in our series, which could be attributable to geographic and/or race-ethnic reasons, or just the representation of the increasing trend in lung adenocarcinoma globally.[@b21-ott-10-5173],[@b22-ott-10-5173]

The prevalence of EGFR mutations is particularly high among East Asian patients with non-small-cell lung cancer, especially among female never smokers.[@b23-ott-10-5173] In Taiwan, the incidence of EGFR-TKI-sensitive mutations among male smokers ranges from 25% to 57% and more than 60% among female never smokers.[@b10-ott-10-5173],[@b23-ott-10-5173],[@b24-ott-10-5173] In this study, the proportion of EGFR-TKI-sensitive mutations was extremely low among patients with HPOA (males, 7.7%; females, 25%). This finding may indicate different underlying pathogeneses among lung cancer patients with HPOA. The EGFR mutation may therefore not be the major driver mutation among these patients. Since HPOA is typically observed in the early stages of lung cancer, factors involved in the pathogenesis, such as PGE2, could be the key factors. PGE2 upregulates the EGFR-stimulated Akt and ERK pathway[@b25-ott-10-5173],[@b26-ott-10-5173] and is associated with lung carcinogenesis and resistance to first-line EGFR-TKI.[@b27-ott-10-5173] Further studies should be conducted to evaluate serum PGE2 level and its interaction with EGFR mutation status. Previous studies reported comparable survival rates between lung cancer patients with and without HPOA,[@b3-ott-10-5173] but lacked data regarding the efficacy of EGFR-TKIs. In our study, we observed shorter progression-free survival and similar overall survival among these 3 patients with EGFR-sensitive mutation who received EGFR-TKIs compared with that reported in previous first-line EGFR-TKIs in TKI-related studies. Further studies should be interesting for evaluation of the treatment response to EGFR-TKIs and efficacy of EGFR-TKIs among non-small-cell lung cancer patients with HPOA harboring sensitive EGFR mutations.

This present study has certain limitations because of its retrospective design. The patients were included on the basis of the presence of typical findings of HPOA on bone scintigraphy rather than clinical presentation. Therefore, we may have not included all lung cancer patients with HPOA, resulting in an underestimation of the incidence. Owing to the limited number of patients, we could not confirm the impact of HPOA on the efficacy of first-line EGFR-TKI treatment. According to previous studies, bone scintigraphy is more sensitive for the detection of the extent of HPOA than radiography. Upon diagnosis of lung cancer, every patient undergoes an initial bone scintigraphy for cancer staging. We usually do not order plain films of the bone for lung cancer patients. Therefore, in contrast with other retrospective studies, we analyzed only bone scintigraphy images but not plain radiography films. In addition, the patients may have had more than one disease other than lung cancer that could have caused periostosis and digital clubbing such as chronic obstructive pulmonary disease, liver cirrhosis, pulmonary tuberculosis, aortic aneurysm, and/or ulcerative colitis. We could not differentiate lung cancer from other diseases based on bone scintigraphy findings. Moreover, owing to the retrospective nature of this analysis we could not confirm whether those certain diseases coexisted or clarify the chronological order of the diseases and lung cancer. Finally, the mechanisms that predispose lung cancer patients to HPOA were not investigated.

Conclusion
==========

This is the first retrospective study to evaluate the clinical significance of HPOA and EGFR mutation status in lung cancer patients. Similar to previous studies, male, smoking, and adenocarcinoma histology were the most common clinical characteristics. Moreover, the proportion of EGFR-TKI-sensitive mutations was extremely low among the included patients. Further studies regarding the mechanisms and impact of HPOA and EGFR status in lung adenocarcinoma patients are warranted.
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###### 

Clinical characteristics of lung cancer patients with HPOA

  -----------------------------------------------------------
  Characteristics            Male\       Female\     Total\
                             N=56 (%)    N=13 (%)    N=69
  -------------------------- ----------- ----------- --------
  Smoker                                             

   Never                     7 (12.5)    11 (84.6)   18

   Ex- or current            49 (87.5)   2 (15.4)    51

  Histology                                          

   Adenocarcinoma            35 (62.5)   7 (53.8)    42

   Squamous cell carcinoma   11 (19.6)   1 (7.7)     12

   Others                    10          5           15

    Adenosquamous            4 (7.1)     2 (15.4)    6

    Large-cell carcinoma     3 (5.3)     2 (15.4)    5

    Sarcomatoid carcinoma    2 (3.6)     1 (7.7)     3

    Small-cell carcinoma     1 (1.8)     0 (0)       1

  Clinical stage                                     

   I                         0 (0)       1 (7.7)     1

   II                        5 (8.9)     1 (7.7)     6

   IIIa                      6 (10.7)    1 (7.7)     7

   IIIb                      7 (12.5)    1 (7.7)     8

   IV                        38 (67.9)   9 (69.2)    47

  EGFR                       26          8           34

   Wild type                 23 (88.5)   6 (75)      29

   Exon 20 insertion         1 (3.8)     0 (0)       1

   Eonx 21 L858R             2 (7.7)     0 (0)       2

   Exon 19 deletion          0 (0)       2 (25)      2
  -----------------------------------------------------------

**Abbreviations:** HPOA, hypertrophic pulmonary osteoarthritis; EGFR, epidermal growth factor receptor.

###### 

Treatment outcome of HPOA patients with EGFR sensitive mutation

  No   Gender   Age   EGFR               Stage   TKIs        PFS (m)   OS (m)
  ---- -------- ----- ------------------ ------- ----------- --------- --------------------------------------------------
  1    Female   77    L858R              Ib      Gefitinib   2.5       36.0[\*](#tfn2-ott-10-5173){ref-type="table-fn"}
  2    Female   53    Exon 19 deletion   IV      Gefitinib   5.9       52.6
  3    Male     68    Exon 19 deletion   IIIb    Erlotinib   8.2       29.0

**Note:**

From cancer recurrence to patient deceased.

**Abbreviations:** (m), months; No, number; EGFR, epidermal growth factor receptor; HPOA, hypertrophic pulmonary osteoarthropathy; TKIs, tyrosine kinase inhibitors; PFS, progression-free survival; OS, overall survival.

###### 

Characteristics of lung cancer patients with HPOA in previous studies

  Author                                  Year   N     Incidence   Male    Smoker   Adenocarcinoma histology   EGFR M+
  --------------------------------------- ------ ----- ----------- ------- -------- -------------------------- ---------
  This study                              2017   69    1.28%       81.2%   73.9%    60.8%                      11.8%
  Qian and Qin[@b18-ott-10-5173]          2014   115   1.87%       91%     76%      48%                        NM
  Ito et al[@b2-ott-10-5173]              2010   19    0.72%       89.4%   94.7%    52.6%                      NM
  Izumi et al[@b19-ott-10-5173]           2010   55    4.5%        70.9%   NM       45%                        NM
  Morgan et al[@b3-ott-10-5173]           1996   28    17%         78.5%   NM       17%                        NM
  Segal and Mackenzie[@b20-ott-10-5173]   1982   16    0.8%        68.8%   100%     38%                        NM

**Abbreviations:** N, patient numbers; EGFR, epidermal growth factor receptor; M+, with sensitive mutation; NM, not mentioned.
